Clene Inc. announced plans to submit a New Drug Application (NDA) for its ALS treatment CNM-Au8 in the third quarter of 2026 following a successful FDA Type C meeting that supported accelerated approval based on biomarker data. The company raised over $35 million through registered direct offerings and amended its debt facility to extend maturity and ease payments. Clene reported a net loss of $8.1 million for Q1 2026 but expects its cash runway to last into late 2026 or early 2027, supported by potential warrant exercises. The company also plans to start a confirmatory Phase 3 trial for CNM-Au8 in early 2027 to further evaluate survival benefits in ALS patients.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
